Cell-Selective Oligonucleotide STAT3 Inhibitor for Immunotherapy of Human Acute Myeloid Leukemia

Journal for ImmunoTherapy of Cancer - United Kingdom
doi 10.1186/2051-1426-3-s2-p362
Full Text
Abstract

Available in full text

Date
Authors
Publisher

BMJ

Related search

Oligonucleotide Aptamer-Drug Conjugates for Targeted Therapy of Acute Myeloid Leukemia

Biomaterials
Mechanics of MaterialsBiophysicsBiomaterialsBioengineeringCompositesNanoscienceNanotechnologyCeramics
2015English

Recent Developments in Immunotherapy of Acute Myeloid Leukemia

Journal of Hematology and Oncology
Cancer ResearchOncologyHematologyMolecular Biology
2017English

The Apoptotic Mechanism of Action of the Sphingosine Kinase 1 Selective Inhibitor SKI-178 in Human Acute Myeloid Leukemia Cell Lines

Journal of Pharmacology and Experimental Therapeutics
Molecular MedicinePharmacology
2015English

B-Cell Lymphoma Immunotherapy Using TLR9-targeted Oligonucleotide STAT3 Inhibitors

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2018English

Acute Myeloid Leukemia Stem Cells and CD33-targeted Immunotherapy

Blood
BiochemistryImmunologyCell BiologyHematology
2012English

Inhibition of CHK1 Enhances Cell Death Induced by the BCL-2-Selective Inhibitor ABT-199 in Acute Myeloid Leukemia Cells

Oncotarget
Oncology
2016English

Acute Myeloid Leukemia

JAMA - Journal of the American Medical Association
Medicine
2010English

Acute Myeloid Leukemia

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2012English

The Cell of Origin and the Leukemia Stem Cell in Acute Myeloid Leukemia

Genes Chromosomes and Cancer
Cancer ResearchGenetics
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy